Sonnet BioTherapeutics Analyst Ratings
Sonnet BioTherapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/15/2023 | 628.26% | EF Hutton | → $6.7 | Reiterates | → Buy |
| 12/19/2022 | 628.26% | EF Hutton | → $6.7 | Initiates Coverage On | → Buy |
| 09/22/2022 | 2291.3% | Chardan Capital | $2 → $22 | Maintains | Buy |
| 08/16/2022 | 117.39% | Chardan Capital | $2.5 → $2 | Maintains | Buy |
| 02/09/2022 | 117.39% | BTIG | $5 → $2 | Maintains | Buy |
| 12/20/2021 | 171.74% | Chardan Capital | $8 → $2.5 | Maintains | Buy |
| 12/16/2021 | 117.39% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 09/15/2021 | 443.48% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 09/04/2020 | 769.57% | Chardan Capital | $7 → $8 | Maintains | Buy |
| 06/05/2020 | 660.87% | Chardan Capital | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 02/15/2023 | 628.26% | EF 赫頓 | → 7 美元 | 重申 | → 購買 |
| 2022 年 12 月 19 日 | 628.26% | EF 赫頓 | → 7 美元 | 啟動覆蓋範圍 | → 購買 |
| 09/22/2022 | 2291.3% | 查丹資本 | 兩美元 → 22 美元 | 維護 | 購買 |
| 2022 年 8 月 16 日 | 117.39% | 查丹資本 | 2.5 美元 → 2 美元 | 維護 | 購買 |
| 2022 年 9 月 2 日 | 117.39% | BTIG | 5 美元 → 2 美元 | 維護 | 購買 |
| 12/20/2021 | 171.74% | 查丹資本 | 八美元 → 2.5 美元 | 維護 | 購買 |
| 12/16/2021 | 117.39% | HC 溫賴特 & 有限公司. | → 2 美元 | 啟動覆蓋範圍 | → 購買 |
| 09/15/2021 | 443.48% | BTIG | → 5 美元 | 啟動覆蓋範圍 | → 購買 |
| 09/04/2020 | 769.57% | 查丹資本 | 7 美元 → 8 美元 | 維護 | 購買 |
| 2020 年 5 月 6 日 | 660.87% | 查丹資本 | → 7 美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Sonnet BioTherapeutics (SONN)?
十四行詩生物治療（SON）的目標價格是多少？
The latest price target for Sonnet BioTherapeutics (NASDAQ: SONN) was reported by EF Hutton on February 15, 2023. The analyst firm set a price target for $6.70 expecting SONN to rise to within 12 months (a possible 628.26% upside). 4 analyst firms have reported ratings in the last year.
EF 赫頓於 2023 年 2 月 15 日報導了十四行詩生物治療（納斯達克股票代碼：SON）的最新價格目標。該分析師公司設定了 6.70 美元的價格目標，預計 SONN 將在 12 個月內上升（可能是 628.26％ 的上漲）。4 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Sonnet BioTherapeutics (SONN)?
十四行詩生物治療學（SON）的最新分析師評級是什麼？
The latest analyst rating for Sonnet BioTherapeutics (NASDAQ: SONN) was provided by EF Hutton, and Sonnet BioTherapeutics reiterated their buy rating.
十四行詩生物治療學（納斯達克代碼：SONN）的最新分析師評級由 EF 赫頓提供，十四行詩生物治療重申了他們的購買評級。
When is the next analyst rating going to be posted or updated for Sonnet BioTherapeutics (SONN)?
什麼時候將發布或更新十四行詩生物治療學（SON）的下一個分析師評級？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.
分析師在做廣泛的研究後到達股票評級，其中包括通過公共財務報表，與十四行詩 BioTheraptics 的高管和客戶交談，以及聽取盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。對於十四行詩生物治療的最後評級提交二月 15, 2023 所以你應該期望下一個評級將在二月左右的某個時候提供 15, 2024.
Is the Analyst Rating Sonnet BioTherapeutics (SONN) correct?
分析師評級十四行詩生物治療學（SON）是否正確？
While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a reiterated with a price target of $0.00 to $6.70. The current price Sonnet BioTherapeutics (SONN) is trading at is $0.92, which is within the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的十四行詩生物治療學（SON）評級重申，目標價格為 0.00 美元至 6.70 美元。目前的價格十四行詩生物治療（SON）的交易價格為 $0.92，這是分析師的預測範圍內。
譯文內容由第三人軟體翻譯。